Combined Modality Therapy Started | peginterferon alfa-2b | Ribavirin
Item
participants who have already begun summary of product characteristics (smpc)-based combination treatment with pegylated interferon alpha-2b and ribavirin, prior to the site initiation date.
boolean
C0009429 (UMLS CUI [1,1])
C1272689 (UMLS CUI [1,2])
C0796545 (UMLS CUI [2])
C0035525 (UMLS CUI [3])
Combined Modality Therapy Previous | peginterferon alfa-2b | Ribavirin
Item
participants who have been receiving combination treatment with pegylated interferon alpha-2b and ribavirin for at least 6 months before enrollment.
boolean
C0009429 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0796545 (UMLS CUI [2])
C0035525 (UMLS CUI [3])
HCV RNA Negative | Hepatitis C virus genotype
Item
participants who have achieved negative hcv rna at the end of treatment, defined according to genotype (24 weeks for hcv genotypes 2/3 and 48 weeks for genotypes 1/4).
boolean
C1868902 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
C1148363 (UMLS CUI [2])
Hepatitis C, Chronic | Hepatitis C virus genotype
Item
participants with diagnosed chronic hepatitis c (chc) and hcv genotype 1, 2, 3 or 4.
boolean
C0524910 (UMLS CUI [1])
C1148363 (UMLS CUI [2])
Age
Item
participants older than 18 years, regardless of gender or race.
boolean
C0001779 (UMLS CUI [1])
Therapeutic procedure Chronic Hepatitis C
Item
the participant has received treatment for chc in the past (not treatment-naive).
boolean
C0087111 (UMLS CUI [1,1])
C0524910 (UMLS CUI [1,2])
Therapeutic procedure | Study Subject Participation Status
Item
the participant has received treatment in the context of a clinical trial in the participating site.
boolean
C0087111 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
Communicable Diseases | Hepatitis B | HIV Infection
Item
the participant has been diagnosed with a concomitant infection e.g. with hepatitis b or hiv
boolean
C0009450 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019693 (UMLS CUI [3])
Decompensated liver disease | Transplantation of liver | Hemophilia | Mental disorders Pre-existing Severe | Autoimmune Diseases | Thalassemia
Item
the participant has de-compensated liver disease or belongs to a special population, such as liver transplant, hemophilia, severe pre-existing psychiatric disorder, auto-immune disease, thalassaemia.
boolean
C4075847 (UMLS CUI [1])
C0023911 (UMLS CUI [2])
C0684275 (UMLS CUI [3])
C0004936 (UMLS CUI [4,1])
C2347662 (UMLS CUI [4,2])
C0205082 (UMLS CUI [4,3])
C0004364 (UMLS CUI [5])
C0039730 (UMLS CUI [6])
HCV RNA Positive
Item
the participant has positive hcv rna at the end of treatment.
boolean
C1868902 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
Pregnancy | Pregnancy, Planned | Partner in relationship Planned Pregnancy | Rebetol
Item
pregnant women or women intending to bear children or sexual partners of women wishing to bear children and for a 7-month period after the end of treatment, as indicated in the smpc of rebetol.
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
C0682323 (UMLS CUI [3,1])
C0032992 (UMLS CUI [3,2])
C1170576 (UMLS CUI [4])
Medical contraindication | Cautionary Warning | Population Specific | Pregnancy | Breast Feeding
Item
the participant is not eligible on grounds of contra-indications, special warnings, particular population and/or the section on pregnancy and lactation of the smpc.
boolean
C1301624 (UMLS CUI [1])
C0871599 (UMLS CUI [2])
C1257890 (UMLS CUI [3,1])
C0205369 (UMLS CUI [3,2])
C0032961 (UMLS CUI [4])
C0006147 (UMLS CUI [5])
Therapy interrupted
Item
the participant has interrupted treatment for any reason.
boolean
C1710384 (UMLS CUI [1])